Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stifel Nicolaus Sticks to Its Buy Rating for CareRx (CRRX)

Tipranks - Tipranks - Tue Apr 21, 8:10AM CDT

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on CareRx, with a price target of C$4.50.

Claim 30% Off TipRanks

Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, HEALWELL AI, and NervGen Pharma. According to TipRanks, Keywood has an average return of -1.5% and a 51.56% success rate on recommended stocks.

CareRx has an analyst consensus of Strong Buy, with a price target consensus of C$5.42.

See today’s best-performing stocks on TipRanks >>

Based on CareRx’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of C$96.08 million and a net profit of C$23.79 million. In comparison, last year the company earned a revenue of C$92.18 million and had a GAAP net loss of C$2.25 million

Based on the recent corporate insider activity of 94 insiders, corporate insider sentiment is neutral on the stock.

Read More on TSE:CRRX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).